Clin J Am Soc Nephrol. 2009;4:1154–5. (Level 6) 2. Sallée M, et al. Clin J Am Soc Nephrol. 2009;4:1183–9. (Level 5) 3. Suwabe T, et al. Nephron Clin Pract. 2009;112:C157–63. (Level 5) 4. Schwab SJ, et al. Am J Med. 1987;82:714–18. (Level 5) 5. Muther
RS, et al. Kidney Int. 1981;20:519–22. (Level 5) selleck chemicals 6. Bennet WM, et al. Am J Kid Dis. 1985;6:400–4. (Level 5) 7. Schwab SJ, et al. Am J Kid Dis. 1983;3:63–6. (Level 5) 8. Elzinga LW, et al. Kidey Int. 1987;32:884–8. (Level 5) 9. Elzinga LW, et al. Antimicrob Agents Chemother. 1988;32:844–7. (Level 5) 10. Telenti A, et al. Mayo Clin Proc. 1990;65:933–42. (Level 5) 11. Rossi SJ, et al. Ann Pharmacother. 1993;27:38–9. (Level 5) 12. Hiyama L, et al. Am J Kidney Dis. 2006;47:E9–13. (Level 5) Do renal volume and the speed of its enlargement reflect the prognosis of renal function? In patients with ADPKD, renal cysts grow exponentially. It has been reported that the median change in eGFR per year was almost 2–5 mL/min/1.73 m2. Since the remaining renal Volasertib parenchyma has the capacity to compensate for
the loss of GFR, the GFR may be sustained until the disease progresses. Although GFR is the usual biomarker of renal disease progression, it does not decrease substantially until extensive and irreversible damage to noncystic parenchyma occurs. Therefore, it is necessary to identify some reliable biomarkers to follow the progression of this disease. Recent data from the American study indicate that kidney check details growth is a critical predictor of progression to renal failure in Caucasian patients with ADPKD, playing a more important
role than hypertension, proteinuria, age, or sex. It was reported that total kidney volume (TKV) increased at a mean rate in the range from 4.0 to 9.4 %, almost 20–50 cm3 per year in several studies. Consequently, TKV growth is considered the best surrogate marker predicting the decline of renal function in ADPKD. Cyclooxygenase (COX) Therefore, since there is no general agreement on the frequency of imaging evaluation, it is reasonable to follow up every 2–5 years in patients with a TKV of 1,000 ml or less and every 1–2 years in patients with a larger TKV. Bibliography 1. Grantham JJ, et al. N Engl J Med. 2006;354:2122–30. (Level 4) 2. Fick-Brosnahan GM, et al. Am J Kidney Dis. 2002;39:1127–34. (Level 4) 3. Tokiwa S, et al. Clin Exp Nephrol. 2011;15:539–45. (Level 4) 4. Cadnapaphornchai MA, et al. Clin J Am Soc Nephrol. 2011;6:369–76. (Level 4) 5. Cadnapaphornchai MA, et al. Kidney Int. 2008;74:1192–6. (Level 4) 6. Helal I, et al. Clin J Am Soc Nephrol. 2011;6:2439–43. (Level 4) 7. Chapman AB, et al. Kidney Int. 2003;64:1035–45. (Level 4) 8. Kistler AD, et al. Kidney Int. 2009;75:235–41. (Level 4) 9. Grantham JJ, et al. Clin J Am Soc Nephrol.